Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma

Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma Edwin P. Rock, Vicki Goodman, Janet X. Jiang, Kooros Mahjoob, S. Leigh Verbois, David Morse, Ramzi Dagher, Robert Justice, Richard Pazdur Oncologist 2007; 12: 107-113 Author Information and Disclosures Target Audience: Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Discuss the mechanism of action of the newly approved targeted cancer drug sunitinib. List the current approved oncology indications for this agent. Describe the pharmacology, metabolism, and side effect profile of sunitinib. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jan. 16, 2007 Most Recent Review: Jan. 16, 2007* Most Recent Update: Jan. 16, 2007 Date Credit Expires: Jan. 16, 2009 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course